National Cancer Institute
U.S. National Institutes of Health | www.cancer.gov

NCI Home
Cancer Topics
Clinical Trials
Cancer Statistics
Research & Funding
News
About NCI
NCI Drug Dictionary
Page Options
Print This Page
More NCI Dictionaries
Dictionary of Cancer Terms

Glossary of Statistical Terms

NCI Dictionary of Genetics Terms

Terminology Resources
Quit Smoking Today
Search for
# A B C D E F G H I J K L M N O P Q R S T U V W X Y Z All

ibritumomab tiuxetanPatient Information
An immunoconjugate of the monoclonal antibody ibritumomab conjugated with the linker-chelator tiuxetan, a high affinity, conformationally restricted chelation site for radioisotopes. When bound to indium In 111 or yttrium Y 90, ibritumomab tiuxetan, targeting the CD20 antigen on B cell surfaces, specifically delivers a potentially cytotoxic dose of radiation to B lymphocytes. Ibritumomab is a murine IgG1 kappa monoclonal antibody directed against the CD20 antigen, which is found on the surface of normal and malignant B lymphocytes. Check for active clinical trials or closed clinical trials using this agent. (NCI Thesaurus)

US brand name:Zevalin



Previous:hypoxia-activated prodrug TH-302, Hytone, I 131 monoclonal antibody CC49, IAP inhibitor HGS1029, ibandronate sodium
Next:ibuprofen, IC-GREEN, ICE regimen, Idamycin, idarubicin

A Service of the National Cancer Institute
Department of Health and Human Services National Institutes of Health USA.gov